MUHC launches world’s first radioligand therapy trial for HER2-positive cancers
The MUHC is the first site in the world to launch a first-in-human Phase I clinical trial evaluating a novel radioligand therapy for HER2-positive cancers, including certain types of breast cancer A highly innovative therapeutic approach for HER2-positive cancers, characterized by the presence of the HER2 protein on the surface…
Spring Convocation
2026 June winner of the Relève étoile Jacques-Genest award
Wajih Jawhar, a Ph.D. candidate in experimental medicine at the Research Institute of the McGill University Health Centre (RI-MUHC), is the recipient of...
July 8, 2026
Guylène Thériault named Family Physician of the Year by the CQMF
The Department of Family Medicine is proud to congratulate Guylène Thériault, MD, PhD, Faculty Lecturer at Campus Outaouais, on being named Family Physician...
July 6, 2026
Gairdner Foundation appoints Canadian Dr. Morag Park as President and Scientific Director
After a rigorous global search process, we are pleased to announce that a renowned cancer scientist and global research leader will succeed Dr....
July 2, 2026
Prativa Baral awarded CIHR’s STEPS Team Grant
CIHR funded team will create a new blueprint for public health emergencies: a pan-Canadian Civilian Emergency Reserve Prativa Baral, Assistant Professor in the...
June 30, 2026
Global clinical trial reveals safest, most effective antibiotics for staphylococcal bloodstream infections
Results from the world’s largest study ever undertaken to improve treatment for Staphylococcus aureus infections—co-led by researchers at the Research Institute of the...
June 30, 2026
MUHC performs a Canadian first to preserve fertility in women with cancer
An innovative uterine transposition procedure protects reproductive organs from damage caused by radiation therapy. A surgical technique designed to preserve fertility in women...
June 23, 2026